Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFS-11
- Development stage
- Preclinical
- Lead developer
- Neurophth
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Ophthalmic
01
Overview
NFS-11 is an investigational gene therapy candidate being developed by Neurophth Therapeutics (Wuhan Kaidejinuo Biotechnology). The program utilizes an adeno-associated virus (AAV) vector to deliver a therapeutic genetic payload to target cells. While the specific molecular target and primary clinical indication for NFS-11 have not been publicly disclosed by the developer, the asset is part of a specialized pipeline focused on gene therapies for rare and common ophthalmic diseases, such as Leber hereditary optic neuropathy (LHON) and glaucoma. As of early 2025, NFS-11 remains in the preclinical stage of development.
Beyond the preview
Go deeper on NFS-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFS-11.